Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nieweg

Showing results (321-330 of 350) with videos related to

Pageof 35
Sort By:
Annals of Surgical Oncology|May 27, 2024
Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 MelanomasAlec A Winder, Zoe Boyer, Sydney Ch'ng, et al.
Annals of Surgical Oncology|December 22, 2019
Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal DiseaseAbhineet Uppal, Stacey Stern, John F Thompson, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomesMary-Ann El Sharouni, Richard A Scolyer, Carla H van Gils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanomaA M Menzies, S N Lo, R P M Saw, et al.
The New England Journal of Medicine|February 14, 2014
Final trial report of sentinel-node biopsy versus nodal observation in melanomaDonald L Morton, John F Thompson, Alistair J Cochran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapyEsther P M Tjin, Debby Konijnenberg, Gabrielle Krebbers, et al.
Annals of Surgical Oncology|August 4, 2021
Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for MelanomaAndrew T Li, Kavita Vakharia, Serigne N Lo, et al.
Journal of the National Cancer Institute|June 15, 2026
Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanomaSophie E Orme, Serigne N Lo, Robyn P Saw, et al.
Annals of Surgical Oncology|June 1, 2012
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)J Harrison Howard, John F Thompson, Nicola Mozzillo, et al.
Annals of Surgical Oncology|April 11, 2006
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional studySandra L Wong, Donald L Morton, John F Thompson, et al.
Pageof 35

Showing results (321-330 of 350) with videos related to

Sort By:
Pageof 35
Annals of Surgical Oncology|May 27, 2024
Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 MelanomasAlec A Winder, Zoe Boyer, Sydney Ch'ng, et al.
Annals of Surgical Oncology|December 22, 2019
Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal DiseaseAbhineet Uppal, Stacey Stern, John F Thompson, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomesMary-Ann El Sharouni, Richard A Scolyer, Carla H van Gils, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanomaA M Menzies, S N Lo, R P M Saw, et al.
The New England Journal of Medicine|February 14, 2014
Final trial report of sentinel-node biopsy versus nodal observation in melanomaDonald L Morton, John F Thompson, Alistair J Cochran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapyEsther P M Tjin, Debby Konijnenberg, Gabrielle Krebbers, et al.
Annals of Surgical Oncology|August 4, 2021
Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for MelanomaAndrew T Li, Kavita Vakharia, Serigne N Lo, et al.
Journal of the National Cancer Institute|June 15, 2026
Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanomaSophie E Orme, Serigne N Lo, Robyn P Saw, et al.
Annals of Surgical Oncology|June 1, 2012
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)J Harrison Howard, John F Thompson, Nicola Mozzillo, et al.
Annals of Surgical Oncology|April 11, 2006
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional studySandra L Wong, Donald L Morton, John F Thompson, et al.
Pageof 35